Research programme: PPAR pan-agonists for CNS disorders - Plexxikon

Drug Profile

Research programme: PPAR pan-agonists for CNS disorders - Plexxikon

Latest Information Update: 10 Mar 2011

Price : $50

At a glance

  • Originator Plexxikon
  • Class Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Alzheimer's disease; Inflammatory bowel diseases; Multiple sclerosis; Parkinson's disease

Most Recent Events

  • 08 Sep 2008 Preclinical development is ongoing in USA
  • 07 Nov 2007 Preclinical trials in Multiple sclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top